MPLT
MapLight Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.29B
P/E Ratio
—
EPS
$-18.56
Beta
—
52W High
$33.28
52W Low
$12.24
50-Day MA
$21.84
200-Day MA
$18.96
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. is an innovative biotechnology company dedicated to developing groundbreaking therapies for serious neurological and psychiatric disorders. Utilizing its proprietary platform, MapLight targets intricate biological pathways to create transformative treatment solutions that enhance patient outcomes. With a commitment to scientific rigor and a promising clinical development pipeline, the company is well-positioned to address critical unmet medical needs, affirming its role as a significant player in the dynamic neurotherapeutics sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-168.50M |
| Operating Margin | 0.00% |
| Return on Equity | -56.20% |
| Return on Assets | -34.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $10.41 |
| Price-to-Book | 2.80 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $42.44M |
| Float | $12.56M |
| % Insiders | 52.02% |
| % Institutions | 52.71% |
Historical Volatility
HV 10-Day
108.81%
HV 20-Day
111.80%
HV 30-Day
97.04%
HV 60-Day
78.70%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($32.67 target)
1
Strong Buy4
BuyData last updated: 5/1/2026